- 01/10/2017 - 30/09/2022
- PEPFAR, Centres for Disease control and Prevention
Efforts in HIV prevention and treatment over the last decade have led to a worldwide reduction of 35% in the number of new HIV infections since 2000 and a 45% reduction in HIV-related deaths. Universal HIV testing and antiretroviral treatment (ART) has been recommended to reach the Joint United Nations Programme on HIV/AIDS 90-90-90 targets and end the AIDS epidemic by 2030. This implies identifying, initiating, and maintaining an additional 11.8 million individuals on ART by 2020 beyond and above the 18.2 million already in ART. However, in resource-limited settings, reaching universal targets is challenging and priorities must be set in order to maximize the efficient use of resources without jeopardizing equity and access to early ART. Fine-tuning a portfolio of strategies for HIV testing and counseling (HTC) and linkage will be necessary to ensure nobody is left behind. Once diagnosed with HIV, linkage and retention is fraught with obstacles which contribute to LTFU at different stages of the continuum of care.
The overarching objective of the VINCI project is to improve efficiency and equity of HTC provision and linkage to ART initiation. More specifically, the VINCI project seeks to evaluate a Ministry of Health training intervention aimed at improving clinician judgment for identifying and offering HTC in the context of Provider Initiated Counselling and Testing (PICT). Also, the project seeks to identify and describe the HIV-positive populations missed by clinician risk-guided PICT prior to and after training.
VINCI is a collaboration between ISGlobal, Fundaçao Manhiça, Fundación Ariel and the Mozambican National Ministry of Health.
2 million USD
- Denise Suzanne Naniche Directora científica
Otros proyectosVer proyectos pasados
Linkage and retention in care following home-based HIV testing serosurveys in Manhiça District, Southern Mozambique
Combatiendo la Resistencia Bacteriana en Europa
Erradicación del Pian
Application to medical deviceswww.nomorfilm.eu
Combatting Bacterial Resistance in Europe - Carbapenem Resistancehttps://www.imi.europa.eu/content/combacte-care
Prioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individualshttps://clinicaltrials.gov/ct2/show/NCT02980016
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Desarrollo de nuevos metaloantibióticos frente a patógenos causantes de infecciones crónicas en pacientes con fibrosis quística
Integrating and decentralizing diabetes and hypertension services in Africahttp://inteafrica.org/
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo
Estudio piloto para evaluar el potencial de la ivermectina para reducir la transmisión de COVID-19http://www.saintproject.org
Measuring community prevalence among HIV exposed children in rural Southern Mozambique
Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant womenwww.mamahproject.net
Predicting the Future: Incipient Tuberculosis